01—Abstract
Summary
Summary of the 10-K filed February 25, 2021. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific's 2020 10-K shows a year transformed by COVID-19 demand.
Revenue rose 26% to $32.22 billiona (up $6.47 billion organically, or 25%, excluding a $133 million currency benefit and a $78 million net acquisition contribution). Management attributes the growth primarily to $6.63 billion of sales of products addressing COVID-19 testing and treatment, concentrated in Life Sciences Solutions (up 77% to $12.17 billion) and Specialty Diagnostics (up 44% to $5.34 billion). Operating income nearly doubled... more precisely, it rose 70% to $7.79 billion, with operating margin expanding from 18.0% to 24.2%.
Net income rose to $6.38 billionb ($15.96 diluted EPS, versus $9.17 in 2019), helped by a lower effective tax rate of 11.8%. The Analytical Instruments segment was the notable laggard, with revenue down 7% to $5.12 billion and segment margin falling to 15.8%, reflecting industrial and academic customer closures during the pandemic. The company ended the year with $10.33 billion in cash, $21.74 billion in debt, and operating cash flow of $8.29 billion (up from $4.97 billion).
It also repurchased $1.50 billionc of stock, paid $337 million in dividends, and began 2021 with $853 million (Novasep viral vector business) and $450 million (Mesa Biotech) acquisitions pending or completed, along with approximately $197 million of debt extinguishment losses. For investors, the key questions are durability and quality of earnings. Management expects COVID-related revenue to continue into 2021 but states that its duration is uncertain and depends on customer testing demand.
The 2021 effective tax rate guidance of 11% to 13% and the $2.2 to $2.4 billiond capital expenditure plan both point to continued heavy investment. The filing also flags risks around goodwill ($26.04 billion) and intangible asset valuations, supply-chain concentration, pending litigation, and the Analytical Instruments supply-contract charge of $108 million.
02—Key points
Key Highlights
- Record 2020 revenue of $32.22 billion, up 26% year over year, with COVID-19 testing and treatment products contributing $6.63 billion of sales.
- Operating income rose 70% to $7.79 billion, and operating margin expanded roughly 6 points to 24.2%, driven by volume leverage.
- Life Sciences Solutions revenue grew 77% to $12.17 billion, with segment operating margin of 50.2%, while Analytical Instruments declined 7% to $5.12 billion.
- Net income increased to $6.38 billion ($15.96 diluted EPS) from $3.70 billion, aided by an 11.8% effective tax rate versus 9.2% in 2019 and a lower share count.
- Operating cash flow of $8.29 billion (up 67%) funded $1.47 billion of capital expenditures, a $1.50 billion share buyback, and $337 million of dividends.
- Balance sheet strengthened: cash of $10.33 billion against $21.74 billion of debt. Management believes existing resources are sufficient for at least the next 24 months.
- Goodwill ($26.04 billion) and intangibles ($12.69 billion) represent a large share of total assets, leaving the company exposed to future impairment if COVID-driven demand normalizes.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 25, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $32.22B$25.54B | +26.1% |
| R&D Expenses | $1.18B$1.00B | +17.7% |
| SG&A Expenses | $6.93B$6.14B | +12.8% |
| Operating Expenses | $24.42B$20.95B | +16.6% |
| Operating Income | $7.79B$4.59B | +69.7% |
| Interest Expense | $553.00M$676.00M | −18.2% |
| Net Income | $6.38B$3.70B | +72.5% |
| EPS (Basic) | $16.09$9.24 | +74.1% |
| EPS (Diluted) | $15.96$9.17 | +74.0% |
| Shares Outstanding (Basic) | 396.00M400.00M | −1.0% |
| Shares Outstanding (Diluted) | 399.00M403.00M | −1.0% |
05—Questions
Frequently Asked Questions
How much of Thermo Fisher's 2020 growth came from COVID-19 products, and is it sustainable?
COVID-19 testing and treatment products generated about $6.63 billion of 2020 sales, which accounts for most of the roughly $6.47 billion organic revenue increase. Management expects these revenues to continue into 2021 but explicitly states that their duration and magnitude are uncertain and depend mainly on customer testing demand. Investors should treat this portion of revenue as non-recurring until the pandemic's trajectory is clearer.
Why did Analytical Instruments decline while the rest of the company grew?
Analytical Instruments revenue fell 7% to $5.12 billion, as industrial customers slowed or closed during COVID-19 and academic labs closed. Segment margin dropped to 15.8% from 23.1%, due to sales mix, lower volume, a $108 million charge on a long-term electron microscopy supply contract, and strategic growth investments. The segment returned to positive growth in Q4 2020.
Why was the effective tax rate so low, and what should investors expect in 2021?
The 2020 effective tax rate was 11.8%, supported by a $263 million domestication-transaction benefit, $96 million of Swedish foreign tax credits, and a $27 million tax audit settlement benefit, which were partly offset by a $156 million valuation allowance on U.S. foreign tax credits. Management guides to a 2021 effective rate of 11% to 13%, so investors should expect the rate to stay low, though it can swing with discrete items.
How is the company's balance sheet positioned for acquisitions and buybacks?
The company ended 2020 with $10.33 billion of cash and $21.74 billion of total debt, and $3.00 billion of undrawn revolving credit capacity (about $31 million reduced by letters of credit). Short-term debt of $2.63 billion was largely repaid in January 2021, which also triggered about $197 million of debt extinguishment losses. Early 2021 saw $1.50 billion of share repurchases and about $1.00 billion of remaining buyback authorization, along with the Novasep viral vector acquisition (about $853 million) and the Mesa Biotech agreement (about $450 million plus up to $100 million in milestones).
What are the main risks to the investment case highlighted in the filing?
Key risks include a potential post-pandemic decline in COVID-related demand; goodwill and intangible impairment if acquired businesses underperform (goodwill $26.04 billion, intangibles $12.69 billion); dependence on sole-source suppliers and on large customers that are also competitors; exposure to international operations and currency (currency translation added $133 million to 2020 revenue); customer capital-spending cycles; regulatory and product-liability exposure; and cybersecurity or data-privacy events. The company also carries a $1.09 billion liability for unrecognized tax benefits and a $1.80 billion pool of unconditional purchase obligations.
06—Continue